REFERENCES
1. Dehner LP. The evolution of the diagnosis and understanding of
primitive and embryonic neoplasms in children: living through an epoch.
Mod Pathol. 1998 Jul;11(7):669-85.
2. Chiang S, Snuderl M, Kojiro-Sanada S, et al. Primitive
Neuroectodermal Tumors of the Female Genital Tract: A Morphologic,
Immunohistochemical, and Molecular Study of 19 Cases. Am J Surg Pathol.
Jun 2017;41(6):761-772.
3. Chao X, Bi Y, Li L. Ovarian primary primitive neuroectodermal tumor:
a review of cases at PUMCH and in the published literature. Orphanet J
Rare Dis. Jun 19 2019;14(1):147.
4. Ulbright TM, Hattab EM, Zhang S, et al. Primitive neuroectodermal
tumors in patients with testicular germ cell tumors usually resemble
pediatric-type central nervous system embryonal neoplasms and lack
chromosome 22 rearrangements. Mod Pathol 23, 972–980 (2010)
5. Delattre O, Zucman J, Melot T, et al. The Ewing family of tumors–a
subgroup of small-round-cell tumors defined by specific chimeric
transcripts. N Engl J Med. Aug 4 1994;331(5):294-9.
6. Al-Hader AA, Jain A, Al-Nasrallah N, Einhorn LH. Metastatic malignant
transformation of teratoma to primitive neuroectodermal tumor (PNET):
results with PNET-based chemotherapy. Am J Clin Oncol. 2015
Aug;38(4):364-6.
7. Shen L, Qiang T, Li Z, Ding D, Yu Y, Lu S. First-line crizotinib
versus platinum-pemetrexed chemotherapy in patients with advanced
ROS1-rearranged non-small-cell lung cancer. Cancer Med. May
2020;9(10):3310-3318. doi:10.1002/cam4.2972
8. Schöffski P, Kubickova M, Wozniak A, et al. Long-term efficacy update
of crizotinib in patients with advanced, inoperable inflammatory
myofibroblastic tumour from EORTC trial 90101 CREATE. Eur J Cancer. 2021
Oct;156:12-23.
9. Foster JH, Voss SD, Hall DC, et al. Activity of Crizotinib in
Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A
Children’s Oncology Group Study (ADVL0912). Clin Cancer Res. 2021 Jul
1;27(13):3543-3548.
10. Ngo C, Grinda T, Bolieve A, et al. Durable response to crizotinib in
metastatic angiomatoid fibrous histiocytoma with EWSR1-CREB1 fusion and
ALK overexpression. Ann Oncol. 2022 May 12;S0923-7534(22)01164-4.
11. Hasan MK, Nafady A, Takatori A, et al. ALK is a MYCN target gene and
regulates cell migration and invasion in neuroblastoma. Sci Rep. 2013
Dec 20;3:3450.
12. Kramer M, Ribeiro D, Arsenian-Henriksson M, Deller T, Rohrer H.
Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN
and Activated ALK Signaling. J Neurosci. Oct 5 2016;36(40):10425-10439.
doi:10.1523/JNEUROSCI.0183-16.2016
13. Moreno MM, Barrell WB, Godwin A, Guille M, Liu KJ. Anaplastic
lymphoma kinase 1, a neuroblastoma associated gene, is
expressed in neural crest domains during embryonic development of
Xenopus. Gene Expr Patterns. Jun 2021;40:119183.
14. Montavon G, Jauquier N, Coulon A, et al. Wild-type ALK and
activating ALK-R1275Q and ALK-F1174L mutations upregulate Myc and
initiate tumor formation in murine neural crest progenitor cells.
Oncotarget. Jun 30 2014;5(12):4452-66.
15. Debruyne DN, Bhatnagar N, Sharma B, et al. ALK inhibitor resistance
in ALK(F1174L)-driven neuroblastoma is associated with AXL activation
and induction of EMT. Oncogene. 2016 Jul 14;35(28):3681-91.
16. Mazot P, Cazes A, Dingli F, et al. Internalization and
down-regulation of the ALK receptor in neuroblastoma cell lines upon
monoclonal antibodies treatment. PLoS One.
2012;72:e33581.
17. Umapathy G, Mendoza-Garcia P, Hallberg B, Palmer RH. Targeting
anaplastic lymphoma kinase in neuroblastoma. APMIS. May
2019;127(5):288-302.
18. Zafar A, Wang W, Liu G, et al. Molecular targeting therapies for
neuroblastoma: Progress and challenges. Med Res Rev. Mar
2021;41(2):961-1021.
19. Vasseur A, Cabel L, Geiss R, et al. Efficacy of Lorlatinib in
Primary Crizotinib-Resistant Adult Neuroblastoma Harboring ALK Y1278S
Mutation. JCO Precis Oncol. 2019 Dec;3:1-5.
20. Braun TP, Eide CA, Druker BJ, et al. Response and Resistance to
BCR-ABL1-Targeted Therapies. Cancer Cell. 2020 Apr 13;37(4):530-542.